This document discusses epidermal growth factor receptor (EGFR) inhibitors for the treatment of non-small cell lung cancer. It provides background on EGFR expression in various cancers and the role of EGFR in tumor growth. It describes various EGFR inhibitors including cetuximab, gefitinib and erlotinib. It summarizes several clinical trials that evaluated these drugs as monotherapy or in combination with chemotherapy. It discusses ongoing research questions around patient selection, combination/sequencing of therapies, and use of EGFR inhibitors in other cancer types.